% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Fasching:310360,
author = {P. A. Fasching and C. Brucker and T. Decker and A. Engel
and T. Göhler and C. Jackisch and J. Janssen and A. Köhler
and K. Lüdtke-Heckenkamp and D. Lüftner and F. Marmé and
M. van Mackelenbergh and B. Rautenberg and M. Schmidt and R.
Weide and P. Wimberger$^*$ and E. Kisseleff and C. Pfister
and C. Quiering and C. Roos and A. Wöckel},
title = {{R}eal-world progression-free survival and overall survival
in patients with {HR}+/{HER}2- advanced breast cancer
treated in first-line with ribociclib, endocrine monotherapy
or chemotherapy: {R}esults from the observational {RIBANNA}
study.},
journal = {International journal of cancer},
volume = {nn},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2026-00556},
pages = {nn},
year = {2026},
note = {#NCTZFB9# / epub},
abstract = {Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i)
combined with endocrine therapy are the preferred choice for
first-line treatment of patients with HR+/HER2- locally
advanced/metastatic breast cancer (aBC). The CDK4/6i
ribociclib in combination with an aromatase inhibitor (AI)
or fulvestrant (FUL) has demonstrated significant
progression-free survival (PFS) and overall survival (OS)
benefits for pre- and postmenopausal aBC patients who were
enrolled in the three pivotal MONALEESA trials. Following
the initial approval of ribociclib in 2017, the
non-interventional RIBANNA study was initiated to evaluate
the effectiveness and safety of ribociclib plus AI/FUL
therapy among patients with aBC in a real-world setting. Two
additional treatment cohorts (endocrine monotherapy [ET] and
chemotherapy [CT]) were included to extend the knowledge
about current aBC treatments. A total of 2567 patients were
enrolled in 279 study centers, of whom 1852 were treated
with ribociclib+AI/FUL, 183 were treated with ET, and 139
were treated with CT, who were available for effectiveness
analyses. Median PFS (mPFS) and median OS (mOS) on
first-line treatment with ribociclib+AI/FUL were 35.0 and
76.0 months, respectively. Adjustment for differences in
demographic and baseline characteristics resulted in a
longer mPFS on ribociclib+AI/FUL (34.7 months) compared to
ET (26.4 months) or CT (19.2 months). Adverse events (AEs)
on ribociclib were consistent with those seen in the pivotal
trials, and no new safety signals were observed. The RIBANNA
study confirmed the PFS and OS benefit seen in the MONALEESA
trials. Together with the safety data, this large real-world
dataset supports the favorable risk/benefit profile of
ribociclib in large scale patient populations.},
keywords = {CDK4/6 inhibitors (Other) / metastatic breast cancer
(Other) / observational study (Other) / overall survival
(Other) / ribociclib (Other)},
cin = {DD04},
ddc = {610},
cid = {I:(DE-He78)DD04-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41792052},
doi = {10.1002/ijc.70397},
url = {https://inrepo02.dkfz.de/record/310360},
}